Journal
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2022.827657
Keywords
enhancer; super-enhancer; DNA methylation; histone modification; prognostic model; eRNA; RNA-seq; hepatocellular carcinoma
Categories
Funding
- China Precision Medicine Initiative [2016YFC0906300]
- Research Center for Air Pollution and Health of Zhejiang University
- Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
Ask authors/readers for more resources
This study identifies aberrant enhancers and associated transcriptional dysregulation in hepatocellular carcinoma (HCC) using integrative analysis of various DNA sequencing data. The study also explores the functions and clinical significance of these aberrant enhancers. Furthermore, a prognostic signature based on aberrant enhancers is established with excellent predictive accuracy for overall survival of HCC patients.
Recently, emerging evidence has indicated that aberrant enhancers, especially super-enhancers, play pivotal roles in the transcriptional reprogramming of multiple cancers, including hepatocellular carcinoma (HCC). In this study, we performed integrative analyses of ChIP-seq, RNA-seq, and whole-genome bisulfite sequencing (WGBS) data to identify intergenic differentially expressed enhancers (DEEs) and genic differentially methylated enhancers (DMEs), along with their associated differentially expressed genes (DEE/DME-DEGs), both of which were also identified in independent cohorts and further confirmed by HiC data. Functional enrichment and prognostic model construction were conducted to explore the functions and clinical significance of the identified enhancer aberrations. We identified a total of 2,051 aberrant enhancer-associated DEGs (AE-DEGs), which were highly concurrent in multiple HCC datasets. The enrichment results indicated the significant overrepresentations of crucial biological processes and pathways implicated in cancer among these AE-DEGs. A six AE-DEG-based prognostic signature, whose ability to predict the overall survival of HCC was superior to that of both clinical phenotypes and previously published similar prognostic signatures, was established and validated in TCGA-LIHC and ICGC-LIRI cohorts, respectively. In summary, our integrative analysis depicted a landscape of aberrant enhancers and associated transcriptional dysregulation in HCC and established an aberrant enhancer-derived prognostic signature with excellent predictive accuracy, which might be beneficial for the future development of epigenetic therapy for HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available